CHOSA Oncology Appoints Bill Cronin to Lead US Commercialization
CHOSA Oncology AB has appointed Bill Cronin to lead its US business development and commercialization activities. The move aims to accelerate the market introduction of its Platin-DRP product in the United States.
CHOSA Oncology AB announced on July 10, 2026, the appointment of Bill Cronin to support the company's commercial expansion in the United States. Cronin will lead CHOSA's US business development and commercialization efforts as the company prepares for the market introduction of Platin-DRP® in the world's largest oncology diagnostics market.
Based in Boston's Kendall Square, a significant hub for oncology research and development in the US, Cronin's appointment follows CHOSA's recent clinical progress, including the presentation of data from the ETOP/EORTC study. This strategic placement is intended to leverage the concentration of expertise and resources in the area.
With a broad network and extensive experience in the oncology market, Cronin is expected to play a key role in accelerating the adoption of Platin-DRP. The company aims to capitalize on the growing demand for targeted cancer diagnostics and therapies.
CHOSA Oncology has not detailed a specific timeline for the Platin-DRP launch in the US, but Cronin's leadership is anticipated to be instrumental in executing the company's commercial strategy and expanding its market presence.